
    
      Methodology:

      The study divided in two parts:

        -  Phase I part: dose escalation study of metronomic oral vinorelbine associated with
           durvalumab + tremelimumab combination immunotherapy,

        -  Phase II part: activity study of metronomic oral vinorelbine associated with durvalumab
           + tremelimumab combination immunotherapy.

      Indication:

      Patient eligible to the study are patients with histologically confirmed locally advanced or
      metastatic solid tumours, resistant to conventional therapies, and candidate to experimental
      therapy by local clinical board, from the following primary tumours: head and neck, prostate,
      cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load.
    
  